Uriel Barkai,
Ph.D., CSO

Uriel Barkai, Ph.D., CSO

Dr. Barkai graduated from Tel-Aviv University in physiology and extended his education at the Roche Institute of Molecular Biology (Nutley, NJ) in cell biology. He was recruited to Tel-Aviv University and Serlin Maternity Hospital, where his research team developed techniques for human prenatal diagnosis and studied molecular cross talk between the uterus and the implanting embryo. Before moving to the biomedical industry in 1998, he spent a sabbatical in the Department of Physiology and Biophysics at the University of Illinois at Chicago.

Dr. Barkai brings to the company more than 15 years of expertise in the biotechnology arena where he worked as director, manager, and consultant at numerous companies. Part of his work focused on molecular imaging (Spectrum Dynamics), wound healing (Polyheal), and clinical use of mesenchymal stem cells. In this area, he participated as founder (Bonus Biogroup) and CSO (Pluristem Therapeutics). Most of his efforts have focused on innovations in diabetes. In this field, Dr. Barkai was a senior officer in three companies developing miniature and implanted cell-based glucose sensors (Carmel Biosensors, Glusense Medical, and Carmel StemSense). During the past 6 years he has been the CSO and head of the islet department in Beta-O2 Technologies, Ltd.

Meet the other team members